Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma | Zendy

Carrie R. McDonald | Zendy; Rachel L. Delfanti | Zendy; Anitha Priya Krishnan | Zendy; Kelly M. Leyden | Zendy; Jona A. HattangadiGluth | Zendy; Tyler M. Seibert | Zendy; Roshan Karunamuni | Zendy; Pia Elbe | Zendy; Joshua Kuperman | Zendy; Hauke Bartsch | Zendy; David Piccioni | Zendy; Nathan S. White | Zendy; Anders M. Dale | Zendy; Nikdokht Farid | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma

Author(s) -

Carrie R. McDonald,

Rachel L. Delfanti,

Anitha Priya Krishnan,

Kelly M. Leyden,

Jona A. HattangadiGluth,

Tyler M. Seibert,

Roshan Karunamuni,

Pia Elbe,

Joshua Kuperman,

Hauke Bartsch,

David Piccioni,

Nathan S. White,

Anders M. Dale,

Nikdokht Farid

Publication year - 2016

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/now063

Subject(s) - bevacizumab , fluid attenuated inversion recovery , medicine , effective diffusion coefficient , percentile , imaging biomarker , glioma , cerebral blood volume , nuclear medicine , radiology , oncology , magnetic resonance imaging , chemotherapy , statistics , mathematics , cancer research

Diffusion-weighted imaging has shown initial promise for evaluating response to bevacizumab in patients with high-grade glioma (HGG). However, it is well recognized that the apparent diffusion coefficient (ADC) is influenced by bevacizumab-induced reductions in edema, which may limit its prognostic value. We demonstrate that an advanced diffusion-weighted imaging technique, restriction spectrum imaging (RSI), improves the evaluation of response to bevacizumab because unlike ADC, RSI is not affected by resolution of edema.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research